BioSpace News Archive

Iterative Scopes, a pioneer in precision medicine technologies for gastroenterology, and Provation, the premier software and SaaS provider of clinical productivity and workflow automation solutions, announced today that SKOUT™ has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for adults undergoing colorectal cancer screening or surveillance.

Liquid biopsy cancer testing is one of the most transformational innovations in healthcare for the next decade, directly unlocking better outcomes for patients

Debiopharm (www.debiopharm.com) today announced the launch of a global, open-innovation Challenge to identify an effective method for linking a cytotoxic or traceable payload to small format antibodies, whose crystallizable fragment (Fc) has been removed.

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today announced that company management will participate in-person for a fireside chat at Chardan’s 6th Annual Genetic Medicines Conference being held in New York City on October 3-4, 2022.

Aadi Bioscience, Inc. announced it has entered into a securities purchase agreement with a new accredited investor and certain existing investors to issue and sell an aggregate of 3,373,526 shares of its common stock at a price of $12.50 per share.

Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that Sekar Kathiresan, M.D., a Maze co-founder, has joined the company’s board of directors.

Ensysce Biosciences, Inc. today announced the initiation of PF614-104, ‘A Randomized, Double-blind, Placebo and Active-Controlled, Crossover Study to Evaluate the Oral Abuse Potential of PF614 Compared with Oxycodone Immediate-Release Tablets, and Placebo in Non-Dependent Recreational Opioid Users.’

Affini-T Therapeutics, Inc ., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, has been selected by Endpoints News Editor John Carroll as one of the most promising startups in biotech for his annual report on the Endpoints 11.

Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the “Company”) today announced it has filed a provisional patent application related to metabolic syndromes including obesity.

Celsius Therapeutics, a biotechnology company pioneering new precision medicines for patients with cancer and autoimmune disease by harnessing the power of single-cell RNA sequencing and human biology at scale, today announced the appointments of six scientific advisers.